New landmark scientific review published on the BB-12™ probiotic strain

Novonesis, a global leader in biosolutions, has announced the publication of an in-depth, peer-reviewed scientific review of BB-12™¹ (Bifidobacterium animalis subsp. lactis), the trademark for one of the world’s most researched probiotic strains. Published as part of a special issue in the leading journal Frontiers in Microbiology, the review consolidates decades of research into a single, accessible source – covering mechanisms of action, clinical efficacy, and relevance across life stages. 

A comprehensive review on a comprehensive challenge

Few health challenges are as widespread and disruptive as those related to digestive health. From irregular bowel movements to disruptions in immune regulation, gastrointestinal discomfort affects millions of people across all life stages. As consumers and healthcare professionals increasingly seek scientifically validated solutions, probiotics have emerged as a promising category – yet the evidence can be fragmented and difficult to navigate. The BB-12™ strain, one of the world’s most documented probiotic strains, now has a thorough scientific review that brings clarity and credibility to the conversation.

“It’s very exciting that we’re able to share this with our customers now,”.“We’ve known about the many benefits of the BB-12™ strain for a long time, but this comprehensive review is a powerful tool for anyone working with it. It helps our partners communicate on health benefits with confidence, backed by science,” says Linda Neckmar, Senior Vice President, Human Health. 

A scientific milestone

With over 400 publications and 200 clinical studies on the BB-12™ probiotic strain, the new review brings together an extensive body of evidence, offering a one-stop reference for formulators, healthcare professionals, and brand owners. 

The review details the BB-12™ strain’s:

• Survival in the gastrointestinal tract

• Bile salt tolerance and metabolic activity

• Adherence to intestinal epithelial cells

• Immune modulation

• Impact on gut microbiota and SCFA production

• Clinical efficacy in constipation and infant colic

“This review is a milestone,”“It gives our partners and customers a complete picture of how the BB-12™ strain works and why it’s trusted globally,” says Linda Neckmar.

Gut health and beyond The review also explores the BB-12™ strain’s role in immune function, regular bowel movements and excessive crying and fussing, reinforcing its relevance across life stages – from infants to older adults. As consumer demand for probiotic solutions continues to grow, rigorous science and proof becomes even more important to stand out and make a real difference in people’s lives.

“This is not just a literature summary,”“It’s a rigorous, peer-reviewed manuscript that validates the BB-12™ strain’s mechanisms of action and clinical outcomes. And while this review brings together decades of research, it also opens the door to future discovery. As we continue to learn more about the microbiome and its role in human health, the BB-12™ strain remains a cornerstone for innovation and exploration," says Martin Kullen, Vice President, Human Health Science & Innovation.

The review highlights the BB-12™ strain’s ability to survive the harsh conditions of the gastrointestinal tract, including acidic pH and bile salts, with clinical studies demonstrating live transit of the strain. While colonization is transient, the BB-12™ strain can interact with host epithelial and immune cells, improving barrier function and modulating immune responses. It enhances IgA secretion, reduces inflammation, and promotes beneficial metabolic activity in the gut microbiota, including increased short-chain fatty acid production. Clinical trials show benefits in constipation and infant colic, associated with improved quality of life for caregivers. The review also identifies opportunities for further research into the BB-12™ strain’s mechanisms and potential new health applications.